KRTCAP2

Summary

KRTCAP2 (keratinocyte associated protein 2, HGNC:28942) is a protein-coding gene on chromosome 1q22, encoding Dolichyl-diphosphooligosaccharide–protein glycosyltransferase subunit KCP2 (Q8N6L1). Subunit of STT3A-containing oligosaccharyl transferase (OST-A) complex that catalyzes the initial transfer of a defined glycan (Glc(3)Man(9)GlcNAc(2) in eukaryotes) from the lipid carrier dolichol-pyrophosphate to an asparagine residue within an Asn-X-Ser/Thr consensus motif in….

Enables enzyme activator activity and protein-macromolecule adaptor activity. Involved in protein N-linked glycosylation via asparagine. Part of oligosaccharyltransferase complex.

Source: NCBI Gene 200185 — RefSeq curated summary.

At a glance

• GWAS associations: 31
• Clinical variants (ClinVar): 33 total
• Druggable target: yes
• MANE Select transcript: NM_173852

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28942
Approved symbol	KRTCAP2
Name	keratinocyte associated protein 2
Location	1q22
Locus type	gene with protein product
Status	Approved
Aliases	KCP2
Ensembl gene	ENSG00000163463
Ensembl biotype	protein_coding
OMIM	619029
Entrez	200185

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 9 protein_coding, 3 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000295682, ENST00000461136, ENST00000463527, ENST00000471891, ENST00000482246, ENST00000487350, ENST00000490672, ENST00000491084, ENST00000497317, ENST00000858475, ENST00000858476, ENST00000922702, ENST00000922703, ENST00000922704

RefSeq mRNA: 1 — MANE Select: NM_173852 NM_173852

CCDS: CCDS1096

Canonical transcript exons

ENST00000295682 — 5 exons

Exon	Start	End
ENSE00001252953	155173221	155173304
ENSE00003480478	155172738	155172892
ENSE00003565698	155169408	155169560
ENSE00003597368	155169791	155169857
ENSE00003692185	155172565	155172628

Expression profiles

Bgee: expression breadth ubiquitous, 174 present calls, max score 99.40.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 210.0663 / max 1263.2011, expressed in 1828 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
14904	206.9187	1828
14903	3.1476	1441

Top tissues by expression

240 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	99.40	gold quality
right testis	UBERON:0004534	99.40	gold quality
bone marrow cell	CL:0002092	99.10	gold quality
endocervix	UBERON:0000458	99.10	gold quality
body of pancreas	UBERON:0001150	99.10	gold quality
body of uterus	UBERON:0009853	99.05	gold quality
body of stomach	UBERON:0001161	99.00	gold quality
adenohypophysis	UBERON:0002196	99.00	gold quality
stromal cell of endometrium	CL:0002255	98.99	gold quality
right lobe of thyroid gland	UBERON:0001119	98.99	gold quality
left lobe of thyroid gland	UBERON:0001120	98.97	gold quality
left uterine tube	UBERON:0001303	98.94	gold quality
right ovary	UBERON:0002118	98.90	gold quality
left coronary artery	UBERON:0001626	98.88	gold quality
mucosa of transverse colon	UBERON:0004991	98.87	gold quality
muscle layer of sigmoid colon	UBERON:0035805	98.87	gold quality
minor salivary gland	UBERON:0001830	98.83	gold quality
right coronary artery	UBERON:0001625	98.82	gold quality
right uterine tube	UBERON:0001302	98.79	gold quality
left ovary	UBERON:0002119	98.78	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	98.75	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	98.74	gold quality
smooth muscle tissue	UBERON:0001135	98.73	gold quality
thoracic aorta	UBERON:0001515	98.73	gold quality
ectocervix	UBERON:0012249	98.73	gold quality
ascending aorta	UBERON:0001496	98.72	gold quality
lower esophagus	UBERON:0013473	98.71	gold quality
lower esophagus muscularis layer	UBERON:0035833	98.71	gold quality
left adrenal gland cortex	UBERON:0035825	98.70	gold quality
left adrenal gland	UBERON:0001234	98.68	gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-CURD-88	yes	93.07
E-HCAD-4	yes	57.96
E-CURD-46	yes	52.96
E-HCAD-5	yes	34.20
E-HCAD-1	yes	16.80
E-MTAB-10553	yes	10.24
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 3)

• data strongly support the proposal that KCP2 is a newly identified subunit of the N-glycosylation machinery present in a subset of eukaryotes (PMID:22266900)
• DC2 and KCP2 mediate the interaction between the oligosaccharyltransferase STT3A and the endoplasmic reticulum translocon. (PMID:28860277)
• KRTCAP2 as an immunological and prognostic biomarker of hepatocellular carcinoma. (PMID:36634487)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	krtcap2	ENSDARG00000070386
mus_musculus	Krtcap2	ENSMUSG00000042747
rattus_norvegicus	Krtcap2	ENSRNOG00000020542
drosophila_melanogaster	CG31460	FBGN0051460

Protein

Protein identifiers

Dolichyl-diphosphooligosaccharide–protein glycosyltransferase subunit KCP2 — Q8N6L1 (reviewed: Q8N6L1)

Alternative names: Keratinocyte-associated protein 2

All UniProt accessions (4): A0A6I8PLD9, A0A6I8PLE4, A0A6I8PRU6, Q8N6L1

UniProt curated annotations — full annotation on UniProt →

Function. Subunit of STT3A-containing oligosaccharyl transferase (OST-A) complex that catalyzes the initial transfer of a defined glycan (Glc(3)Man(9)GlcNAc(2) in eukaryotes) from the lipid carrier dolichol-pyrophosphate to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains, the first step in protein N-glycosylation. N-glycosylation occurs cotranslationally and the complex associates with the Sec61 complex at the channel-forming translocon complex that mediates protein translocation across the endoplasmic reticulum (ER). Within the OST-A complex, acts as an adapter that anchors the OST-A complex to the Sec61 complex. May be involved in N-glycosylation of APP (amyloid-beta precursor protein). Can modulate gamma-secretase cleavage of APP by enhancing endoprotelysis of PSEN1.

Subunit / interactions. Component of STT3A-containing oligosaccharyl transferase (OST-A) complex. STT3A-containing complex assembly occurs through the formation of 3 subcomplexes. Subcomplex 1 contains RPN1 and TMEM258, subcomplex 2 contains the STT3A-specific subunits STT3A, DC2/OSTC, and KCP2 as well as the core subunit OST4, and subcomplex 3 contains RPN2, DAD1, and OST48. The OST-A complex can form stable complexes with the Sec61 complex or with both the Sec61 and TRAP complexes. Interacts with PSEN1 and NCSTN; indicative for an association with the gamma-secretase complex.

Subcellular location. Endoplasmic reticulum. Endoplasmic reticulum membrane.

Tissue specificity. Expressed in skin, heart, placental, liver, skeletal muscle, kidney, pancreas, keratinocytes and dermal fibroblasts.

Pathway. Protein modification; protein glycosylation.

Miscellaneous. Produced at low levels due to suboptimal Kozak context.

Similarity. Belongs to the KRTCAP2 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8N6L1-1	1	yes
Q8N6L1-2	2

RefSeq proteins (1): NP_776251* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR018614	KRTCAP2	Family

Pfam: PF09775

UniProt features (13 total): topological domain 4, transmembrane region 3, chain 1, splice variant 1, sequence variant 1, sequence conflict 1, short sequence motif 1, modified residue 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
9N9J	ELECTRON MICROSCOPY	3.2
9YGY	ELECTRON MICROSCOPY	4.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N6L1-F1	82.91	0.60

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 124

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 162 (showing top): TGCGCANK_UNKNOWN, GOBP_PROTEIN_N_LINKED_GLYCOSYLATION, GCANCTGNY_MYOD_Q6, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, MAZ_Q6, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GGGTGGRR_PAX4_03, CAGCTG_AP4_Q5, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOLDRATH_ANTIGEN_RESPONSE, SRF_Q5_01, MARTINEZ_RB1_TARGETS_UP, SRF_C, WANG_LMO4_TARGETS_DN, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM1

GO Biological Process (3): protein N-linked glycosylation (GO:0006487), obsolete protein N-linked glycosylation via asparagine (GO:0018279), obsolete protein glycosylation (GO:0006486)

GO Molecular Function (2): enzyme activator activity (GO:0008047), protein-macromolecule adaptor activity (GO:0030674)

GO Cellular Component (5): endoplasmic reticulum membrane (GO:0005789), oligosaccharyltransferase complex (GO:0008250), oligosaccharyltransferase complex A (GO:0160226), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
glycoprotein biosynthetic process	1
catalytic activity	1
enzyme regulator activity	1
molecular function activator activity	1
protein binding	1
molecular adaptor activity	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
endoplasmic reticulum membrane	1
membrane protein complex	1
endoplasmic reticulum protein-containing complex	1
transferase complex	1
oligosaccharyltransferase complex	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

920 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KRTCAP2	OSTC	Q9NRP0	913
KRTCAP2	DAD1	P46966	856
KRTCAP2	STT3A	P46977	831
KRTCAP2	TMEM258	P61165	820
KRTCAP2	DDOST	P39656	780
KRTCAP2	STT3B	Q8TCJ2	780
KRTCAP2	TUSC3	Q13454	737
KRTCAP2	RPN1	P04843	734
KRTCAP2	MAGT1	Q9H0U3	731
KRTCAP2	RPN2	P04844	730
KRTCAP2	OST4	P0C6T2	726
KRTCAP2	TRIM46	Q7Z4K8	707
KRTCAP2	ERG28	Q9UKR5	664
KRTCAP2	IER3IP1	Q9Y5U9	570
KRTCAP2	EMC7	Q9NPA0	514

IntAct

33 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
RPN1	APBB1	psi-mi:“MI:0914”(association)	0.530
CREB3	KRTCAP2	psi-mi:“MI:0915”(physical association)	0.370
	KRTCAP2	psi-mi:“MI:0915”(physical association)	0.370
HSCB	RBP5	psi-mi:“MI:0914”(association)	0.350
	TSPO	psi-mi:“MI:0914”(association)	0.350
CANX	HLA-A	psi-mi:“MI:0914”(association)	0.350
DAD1	PGRMC1	psi-mi:“MI:0914”(association)	0.350
DDOST	ATL3	psi-mi:“MI:0914”(association)	0.350
DRG1	RPS3A	psi-mi:“MI:0914”(association)	0.350
KRTCAP2	PGRMC1	psi-mi:“MI:0914”(association)	0.350
OST4	ATL3	psi-mi:“MI:0914”(association)	0.350
OSTC	PGRMC1	psi-mi:“MI:0914”(association)	0.350
PGRMC1	NBAS	psi-mi:“MI:0914”(association)	0.350
RACK1	RPS3A	psi-mi:“MI:0914”(association)	0.350
RBM14	TBKBP1	psi-mi:“MI:0914”(association)	0.350
RBM42	RPS3A	psi-mi:“MI:0914”(association)	0.350
RPN2	APBB1	psi-mi:“MI:0914”(association)	0.350
VAPA	ESYT2	psi-mi:“MI:0914”(association)	0.350
TIA1	RPN1	psi-mi:“MI:0914”(association)	0.350
KRTCAP2	PLSCR1	psi-mi:“MI:0914”(association)	0.350
KRTCAP2	RAP2B	psi-mi:“MI:0914”(association)	0.350
P/V	ESYT2	psi-mi:“MI:0914”(association)	0.350
NRAS	IGKV2D-24	psi-mi:“MI:0914”(association)	0.350
TCTN3	TMEM120B	psi-mi:“MI:2364”(proximity)	0.270
TCTN2	TMEM120B	psi-mi:“MI:2364”(proximity)	0.270
SCLT1	VWA8	psi-mi:“MI:2364”(proximity)	0.270
VHL	KRTCAP2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (89): STT3A (Affinity Capture-Western), STT3B (Affinity Capture-Western), KRTCAP2 (Two-hybrid), KRTCAP2 (Proximity Label-MS), KRTCAP2 (Proximity Label-MS), KRTCAP2 (Proximity Label-MS), KRTCAP2 (Two-hybrid), KRTCAP2 (Synthetic Lethality), KRTCAP2 (PCA), KRTCAP2 (PCA), KRTCAP2 (Affinity Capture-MS), KRTCAP2 (Proximity Label-MS), RMND1 (Affinity Capture-MS), CXCR4 (Affinity Capture-MS), IFITM1 (Affinity Capture-MS)

ESM2 similar proteins: A4IFN5, A6NI61, A6QQ59, B0CM95, B2KI79, B2LYG4, B2RZC9, D0Q0Y7, O35089, P22234, P86229, Q15546, Q1RMP9, Q2TA01, Q3ZCD7, Q5BJU5, Q5QJU3, Q5R589, Q5RB59, Q5RDB5, Q5RL79, Q5U3C3, Q64232, Q6IQ69, Q6PHN7, Q6PI25, Q6ZWS4, Q719N3, Q865K8, Q86WK9, Q86YN1, Q8BWB6, Q8IY49, Q8IZV2, Q8N6L1, Q8N6M3, Q8NBT3, Q8NFT2, Q8R189, Q8TBE1

Diamond homologs: A6QQ59, B2RZC9, P86229, Q1HQF8, Q295N5, Q5Q995, Q5RL79, Q8INQ7, Q8N6L1, Q54L98

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 39 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
PD-L1(CD274) glycosylation and translocation to plasma membrane	6	97.3×	2e-09
Regulation of CDH1 posttranslational processing and trafficking to plasma membrane	7	73.5×	9e-10
Maturation of spike protein	7	58.1×	2e-09
Maturation of DENV proteins	7	46.3×	7e-09
Asparagine N-linked glycosylation	7	13.2×	4e-05

GO biological processes:

GO term	Partners	Fold	FDR
obsolete protein N-linked glycosylation via asparagine	5	93.6×	5e-07
protein N-linked glycosylation	6	43.9×	6e-07

Disease & clinical

Clinical variants and AI predictions

ClinVar

33 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	22
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1060 predictions. Top by Δscore:

Variant	Effect	Δscore
1:155169858:C:CC	acceptor_gain	0.9900
1:155172327:C:A	donor_gain	0.9900
1:155173194:T:TA	donor_gain	0.9900
1:155170599:C:CA	donor_gain	0.9800
1:155172563:A:AC	donor_gain	0.9800
1:155172564:C:CC	donor_gain	0.9800
1:155172564:CT:C	donor_gain	0.9800
1:155172778:C:CA	donor_gain	0.9800
1:155172326:T:TA	donor_gain	0.9700
1:155172564:CTCT:C	donor_gain	0.9700
1:155173224:T:C	donor_gain	0.9600
1:155172208:T:TA	donor_gain	0.9500
1:155173212:T:TA	donor_gain	0.9500
1:155169561:C:CC	acceptor_gain	0.9400
1:155172208:TC:T	donor_gain	0.9400
1:155172221:C:CA	donor_gain	0.9400
1:155172890:CCA:C	acceptor_gain	0.9400
1:155172891:CAC:C	acceptor_gain	0.9400
1:155173182:C:CA	donor_gain	0.9400
1:155172205:A:C	donor_gain	0.9300
1:155172362:G:A	donor_gain	0.9300
1:155172545:AAGCT:A	donor_gain	0.9300
1:155172893:C:CC	acceptor_gain	0.9300
1:155173195:C:A	donor_gain	0.9200
1:155172307:G:A	donor_gain	0.9100
1:155169630:CA:C	acceptor_gain	0.9000
1:155172321:A:T	donor_gain	0.9000
1:155173110:C:CA	donor_gain	0.9000
1:155169632:C:CC	acceptor_gain	0.8900
1:155171337:TGA:T	donor_gain	0.8900

AlphaMissense

1035 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000388388 (1:155174402 G>A,T), RS1000594297 (1:155174474 C>G), RS1000687791 (1:155173146 G>A,T), RS1001596146 (1:155172988 C>A,T), RS1002542742 (1:155173437 C>G,T), RS1002695606 (1:155169678 G>A,C,T), RS1002747663 (1:155169325 A>G), RS1003014142 (1:155171490 G>C), RS1003819564 (1:155170090 G>A), RS1004061486 (1:155170562 A>G), RS1006486233 (1:155171883 G>A), RS1006706192 (1:155172069 A>ATT), RS1007712368 (1:155170896 T>C), RS1007743361 (1:155170545 TGA>T), RS1008293165 (1:155175210 A>C,G)

Disease associations

OMIM: gene MIM:619029 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

31 associations (top):

Study	Trait	p-value
GCST004131_70	Inflammatory bowel disease	6.000000e-08
GCST004132_44	Crohn’s disease	2.000000e-07
GCST007045_14	PR interval	6.000000e-10
GCST007293_59	Body fat distribution (arm fat ratio)	6.000000e-08
GCST007293_94	Body fat distribution (arm fat ratio)	4.000000e-11
GCST007294_124	Body fat distribution (trunk fat ratio)	8.000000e-35
GCST007294_3	Body fat distribution (trunk fat ratio)	6.000000e-21
GCST007294_50	Body fat distribution (trunk fat ratio)	1.000000e-15
GCST007295_17	Body fat distribution (leg fat ratio)	3.000000e-13
GCST007295_37	Body fat distribution (leg fat ratio)	7.000000e-17
GCST007295_72	Body fat distribution (leg fat ratio)	1.000000e-28
GCST007430_19	Peak expiratory flow	8.000000e-09
GCST007431_112	Lung function (FEV1/FVC)	1.000000e-20
GCST008295_16	Number of decayed, missing and filled tooth surfaces or use of dentures	7.000000e-15
GCST008306_23	Dentures	3.000000e-13
GCST008767_2	Perceived intensity of sucrose	4.000000e-07
GCST008794_18	Urinary albumin-to-creatinine ratio	2.000000e-15
GCST009325_27	Parkinson’s disease or first degree relation to individual with Parkinson’s disease	2.000000e-70
GCST009640_5	Urinary albumin-to-creatinine ratio	5.000000e-12
GCST010002_367	Refractive error	5.000000e-13
GCST010321_101	PR interval	2.000000e-25
GCST010696_19	Cortical thickness (min-P)	2.000000e-10
GCST010697_10	Cortical surface area (min-P)	3.000000e-10
GCST010698_59	Subcortical volume (min-P)	9.000000e-10
GCST010699_20	Brain morphology (min-P)	7.000000e-10
GCST010700_5	Cortical thickness (MOSTest)	8.000000e-17
GCST010701_66	Cortical surface area (MOSTest)	1.000000e-09
GCST010702_43	Subcortical volume (MOSTest)	3.000000e-10
GCST010703_253	Brain morphology (MOSTest)	4.000000e-14
GCST010984_3	Allergic disease (asthma, hay fever and/or eczema) (multivariate analysis)	2.000000e-08

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0004462	PR interval
EFO:0004341	body fat distribution
EFO:0009718	peak expiratory flow
EFO:0004713	FEV/FVC ratio
EFO:0010078	dentures
EFO:0007778	urinary albumin to creatinine ratio
EFO:0004346	neuroimaging measurement
EFO:0004840	cortical thickness
EFO:0004847	age at onset

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067100 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.78	Kd	164.5	nM	CHEMBL3752910
6.78	ED50	164.5	nM	CHEMBL3752910
5.12	Kd	7592	nM	CHEMBL5653589
5.12	ED50	7592	nM	CHEMBL5653589

PubChem BioAssay actives

2 with measured affinity, of 4 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148631: Binding affinity to human KRTCAP2 incubated for 45 mins by Kinobead based pull down assay	kd	0.1645	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148631: Binding affinity to human KRTCAP2 incubated for 45 mins by Kinobead based pull down assay	kd	7.5923	uM

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, increases methylation	3
Cyclosporine	increases expression	3
Tunicamycin	increases expression	2
Thapsigargin	increases expression	2
FR900359	decreases phosphorylation	1
bisphenol A	affects expression	1
isobutyl alcohol	affects cotreatment, decreases expression, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
chloropicrin	increases expression	1
ICG 001	increases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, increases expression	1
bisphenol S	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Catechin	increases expression, affects cotreatment	1
Cisplatin	decreases expression	1
Cycloheximide	affects cotreatment, increases expression	1
Dexamethasone	increases expression, affects cotreatment	1
Diuron	decreases expression	1
Gasoline	affects cotreatment, decreases expression, increases abundance	1
Indomethacin	affects cotreatment, increases expression	1
Ivermectin	decreases expression	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, decreases expression, increases abundance	1
Smoke	decreases expression	1
Tetrachlorodibenzodioxin	affects cotreatment, increases expression	1
Thiram	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Cadmium Chloride	decreases expression	1
1-Butanol	affects cotreatment, decreases expression, increases abundance	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651673	Binding	Binding affinity to human KRTCAP2 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2ZX	Abcam HEK293T KRTCAP2 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.